<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131167</url>
  </required_header>
  <id_info>
    <org_study_id>SHP639-101</org_study_id>
    <nct_id>NCT03131167</nct_id>
  </id_info>
  <brief_title>Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma</brief_title>
  <official_title>A Randomized, Double-masked, Placebo-controlled Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Daily and Multiple Daily Ascending Doses of SHP639 Topical Ophthalmic Solution in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma (POAG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and tolerability of three different concentrations (0.1%, 03%, 0.6%) of the
      investigational SHP639 eye drops will be evaluated in participants with high eye pressure or
      primary open-angle glaucoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Actual">May 30, 2018</completion_date>
  <primary_completion_date type="Actual">May 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Event (TEAE)</measure>
    <time_frame>From start of study drug administration up to follow-up (Day 88)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Intra Ocular Pressure (IOP) at Day 29</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <description>IOP was measured using Goldmann applanation tonometry and reported data from baseline at day 29 for both study eye and non study eye.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Primary Open-angle Glaucoma (POAG)</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>SHP639 Ophthalmic Solution Arm (n=60)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are divided into groups called cohorts. There will be approximately 12 cohorts, each consisting of 7 participants. In each cohort 5 out of 7 participants will be assigned a specified concentration of SHP639 (0.1%, 0.3%, or 0.6%) ophthalmic solution and a specific dosing schedule (the study participants will be instructed to insill the study drug one, two, three, or four times a day) in both eyes during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Ophthalmic Arm (n=24)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In each cohort 2 out of 7 participants will be assigned a placebo ophthalmic solution matched to 0.1%, 0.3%, and 0.6% SHP639 ophthalmic solution and specific dosing schedule (the study participants will be instructed to instill the study drug one, two, three, or four times a day) in both eyes during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP639 (n=60)</intervention_name>
    <description>Drug SHP639 is a 9-amino acid, synthetic, C-type natriuretic peptide (CNP) analog.</description>
    <arm_group_label>SHP639 Ophthalmic Solution Arm (n=60)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator (n=24)</intervention_name>
    <description>Drug: Vehicle Ophthalmic placebo solution of the same composition as the test product.</description>
    <arm_group_label>Vehicle Ophthalmic Arm (n=24)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants must provide written, signed and dated informed consent to participate in
             the study in accordance with the International Council for Harmonisation (ICH) Good
             Clinical Practice (GCP) Guideline E6(R1) and applicable regulations, before completing
             any study-related procedures.

          2. Participants must be aged from 18 through 90 at the time of consent. This inclusion
             criterion will only be assessed at the screening visit.

          3. Participants must have ocular hypertension (OHT) or stable early primary open-angle
             glaucoma (POAG) in both eyes with acceptable Humphrey visual fields (HVF). Early POAG
             for this protocol is defined as healthy appearing anterior chamber angles (Shaffer
             classification system grade 3 or 4) and focal and/or generalized thinning of the optic
             disc rim characteristic of glaucomatous disease. An acceptable HVF must have been
             performed within approximately one year of screening, have a false-positive rate of 25
             percent (%) maximum, false-negative rate of 25% maximum, and fixation loss rate of 33%
             maximum, and mean deviation of no worse than -6.00 decibels (dB).

          4. On Day -1, participants must have a mean IOP of greater than or equal to (&gt;=) 24
             millimeter of mercury (mmHg) at 8:00 AM and a mean IOP of &gt;= 22 mmHg at 10:00 AM in at
             least 1 eye, with an IOP difference of less than (&lt;) 4 mmHg between eyes at both of
             these time points. If only 1 eye meets this criterion, then it will be the designated
             study eye for pharmacodynamic analysis; this eye will also be used for dosing in
             Cohort A single-dose treatment period (SDTP).

          5. Participants must have a best-corrected visual acuity (BCVA) in both eyes of 65
             letters on the Early Treatment Diabetic Retinopathy Study chart (Snellen equivalent
             approximately [âˆ¼] 20/60) or better at the screening and baseline assessments.

          6. Participants must be males or females who are non-pregnant and non-lactating at
             screening (negative serum beta-human chorionic gonadotropin [beta-hCG]); if sexually
             active during the study, they must agree to comply with the applicable contraceptive
             requirements throughout the study period and for 60 days following the last dose of
             investigational product.

          7. Participants must have a satisfactory medical assessment with no clinically
             significant or relevant abnormalities as determined by medical history, physical
             examination, and clinical and laboratory evaluation (hematology, biochemistry,
             urinalysis) as assessed by the investigator.

          8. Participants must understand and be able, willing, and likely to fully comply with
             study procedures and restrictions.

          9. Participants must be non-smokers or have had stable use of tobacco or
             nicotine-containing products for a 3-month period before signing the informed consent
             form (ICF).

         10. Participants who drink alcohol must have had stable use of alcohol for a 3-month
             period before signing the ICF.

        Exclusion Criteria:

          1. Participant has an anatomically narrow angle, synechiae or evidence of prior
             inflammation, angle closure glaucoma, normal tension glaucoma, pseudoexfoliation
             syndrome or pigmentary dispersion syndrome with or without glaucoma, or secondary
             glaucoma.

          2. Participant has corneal endothelial cell counts of less than 2000 cells per
             millimeter^2 (measured by noncontact specular microscopy) at the screening or baseline
             assessments.

          3. Participant has central corneal thickness less than 500 micrometer (mcm) or greater
             than 620 mcm at the screening or baseline assessments.

          4. Participant has IOP greater than 32 mmHg in either eye before randomization.

          5. Participant has used topical ocular hypotensive medications as follows: prostaglandin
             analogs, beta-adrenoceptor antagonists, alpha-adrenergic agonists, or
             epinephrine-related medications within 4 weeks before the first dose of
             investigational product; or pilocarpine or carbonic anhydrase inhibitors within 7 days
             before the first dose of investigational product.

          6. Participant has a history of angle closure, ocular surgery, microinvasive glaucoma
             surgery device insertion, or laser surgery, except for the following procedures, which
             are allowed: uncomplicated cataract surgery, laser peripheral iridotomy with resultant
             angle of Shaffer grade 3 or 4, and postcataract neodymium-doped
             yttrium-aluminum-garnet (Nd:YAG) laser posterior capsulotomy. Cataract surgery and
             other procedures must have occurred a minimum of 3 months before randomization.

          7. Participant has a history of significant ocular trauma or ocular disease including but
             not limited to moderate to severe dry eye disease that requires chronic treatment or
             punctal plugs.

          8. Participant has evidence of ocular infection, inflammation, degeneration, or dystrophy
             at the screening or baseline assessments, including but not limited to moderate to
             severe blepharitis (mild blepharitis is allowed), conjunctivitis (allergic or
             infectious), corneal dystrophy (epithelial, stromal, or endothelial), corneal haze of
             grade 1 or greater based on the Hwang Grading Scale of Corneal Haze, corneal
             opacities, keratitis, uveitis, or vitritis.

          9. Participant has retinal disease including but not limited to: moderate or severe
             non-proliferative diabetic retinopathy (NPDR) (early NPDR is allowed), proliferative
             diabetic retinopathy, intermediate or advanced dry age-related macular degeneration
             (AMD) (early dry AMD is allowed), all geographic atrophy, or all wet AMD.

         10. Participant has any non-glaucomatous optic neuropathy or other significant
             non-glaucomatous ocular disease that is likely to affect visual function.

         11. Participant has any corneal or ocular surface pathology in either eye that prevents
             proper IOP measurement, pachymetry, or other study data collection procedures.

         12. Participant has had changes to their existing prescription medication regimen for
             chronic disease, including those medicines that affect IOP, within 14 days or 5
             half-lives before screening, whichever is longer.

         13. Participant has started any new prescription drug medication for chronic disease,
             including those medicines that affect IOP, within 14 days or 5 half-lives before
             screening, whichever is longer.

         14. Participant has a history of corticosteroid use within 3 months before randomization,
             except for non-periocular dermatologic use, which is allowed.

         15. Participant has used belladonna alkaloids (scopolamine, hyoscamine, atropine) within 7
             days prior to randomization, cannabinoids or opioids within 28 days before
             randomization, or B-type natriuretic peptides within the past year before
             randomization; or a participant has an anticipated need for any of the aforementioned
             drugs/drug categories during the study.

         16. Participant has used amantadine within 28 days before randomization.

         17. Participant is unable to discontinue contact lens use during and for 60 minutes
             following instillation of study medication, during ophthalmologic examinations, and
             during study visits.

         18. Participant has a current or relevant history of any physical, medical, mental, or
             psychiatric illness, disorder, or condition that may require treatment during the
             study and/or that may interfere with the participant complying with the study rules
             and procedures or completing the study.

         19. Participant has any condition that presents undue risk from use of the investigational
             product, assessment tools, or procedures.

         20. Participant is a woman who is pregnant (positive serum beta-hCG pregnancy test at the
             time of screening), lactating, or less than 90 days post-partum at randomization.

         21. Participant has donated blood within 60 days before first dose of investigational
             product.

         22. Participant has donated plasma within 28 days before first dose of investigational
             product.

         23. Participant has used another investigational product within 30 days before the first
             dose of investigational product or is actively enrolled in a drug or vaccine clinical
             study.

         24. Participant has a positive human immunodeficiency virus (HIV), hepatitis B surface
             antigen (HBsAg), or hepatitis C virus (HCV) antibodies screen.

         25. Participant has a positive drugs of abuse screen or alcohol breathalyzer test.

         26. Participant has been previously enrolled in this study.

         27. Participant has known hypersensitivity or allergy to any of the ingredients of the
             investigational product.

         28. Participant consumes more than 21 units of alcohol per week or is unable to refrain
             from alcohol consumption within 48 hours before a scheduled visit. (1 alcohol unit=1
             beer or 1 wine [5 ounce per 150 milliliter] or 1 liquor [1.5 ounce per 40 milliliter]
             or 0.75 ounce alcohol.)

         29. Participant is unable to refrain from tobacco or any products containing nicotine
             within 8 hours before a scheduled visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Contact</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <zip>02421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <results_first_submitted>May 29, 2019</results_first_submitted>
  <results_first_submitted_qc>August 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2019</results_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03131167/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03131167/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 4 study centers in the United States between 10 May 2017 (first participant first visit) and 30 May 2018 (last participant last visit).</recruitment_details>
      <pre_assignment_details>Totally, 63 participants enrolled, randomized and received treatment in two parts of the study with one cohort for one dose level (Part 1: Cohort A1, A2, A3, with single dose and QD multiple dose, followed by Cohort B1, B2, B3 with BID multiple dose. Part 2: Cohort C1, C2, C3 with TID multiple dose, followed by D1, D2, D3 with QID multiple dose).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo QD</title>
          <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.1%, 0.3%, 0.6% respectively applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
        </group>
        <group group_id="P2">
          <title>SHP639 0.1% QD</title>
          <description>Participants received one drop of SHP639 at a dose of 0.1% applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
        </group>
        <group group_id="P3">
          <title>SHP639 0.3% QD</title>
          <description>Participants received one drop of SHP639 at a dose of 0.3% applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
        </group>
        <group group_id="P4">
          <title>SHP639 0.6% QD</title>
          <description>Participants received one drop of SHP639 at a dose of 0.6% applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
        </group>
        <group group_id="P5">
          <title>Placebo BID</title>
          <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.1%, 0.3%, 0.6% respectively applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
        </group>
        <group group_id="P6">
          <title>SHP639 0.1% BID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.1% applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
        </group>
        <group group_id="P7">
          <title>SHP639 0.3% BID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.3% applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
        </group>
        <group group_id="P8">
          <title>SHP639 0.6% BID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.6% applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
        </group>
        <group group_id="P9">
          <title>Placebo Repeated BID</title>
          <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.6% applied topically in the designated eye and non study eye twice daily (BID) during the repeated twice daily dose regimen.</description>
        </group>
        <group group_id="P10">
          <title>SHP639 0.6% Repeated BID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.6% applied topically in both the designated eye and non study eye twice daily (BID) during the repeated twice daily dose regimen.</description>
        </group>
        <group group_id="P11">
          <title>Placebo TID</title>
          <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.1%, 0.3%, 0.6% respectively applied topically in the designated eye and non study eye thrice daily (TID) during the thrice daily dose regimen.</description>
        </group>
        <group group_id="P12">
          <title>SHP639 0.1% TID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.1% applied topically in the designated eye and non study eye thrice daily (TID) during the thrice daily dose regimen.</description>
        </group>
        <group group_id="P13">
          <title>SHP639 0.3% TID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.3% applied topically in the designated eye and non study eye thrice daily (TID) during the thrice daily dose regimen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other (Unspecified)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized set consisted of all participants in the enrolled set for whom a randomization number was assigned.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo QD</title>
          <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.1%, 0.3%, 0.6% respectively applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
        </group>
        <group group_id="B2">
          <title>SHP639 0.1% QD</title>
          <description>Participants received one drop of SHP639 at a dose of 0.1% applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
        </group>
        <group group_id="B3">
          <title>SHP639 0.3% QD</title>
          <description>Participants received one drop of SHP639 at a dose of 0.3% applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
        </group>
        <group group_id="B4">
          <title>SHP639 0.6% QD</title>
          <description>Participants received one drop of SHP639 at a dose of 0.6% applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
        </group>
        <group group_id="B5">
          <title>Placebo BID</title>
          <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.1%, 0.3%, 0.6% respectively applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
        </group>
        <group group_id="B6">
          <title>SHP639 0.1% BID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.1% applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
        </group>
        <group group_id="B7">
          <title>SHP639 0.3% BID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.3% applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
        </group>
        <group group_id="B8">
          <title>SHP639 0.6% BID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.6% applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
        </group>
        <group group_id="B9">
          <title>Placebo Repeated BID</title>
          <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.6% applied topically in the designated eye and non study eye twice daily (BID) during the repeated twice daily dose regimen.</description>
        </group>
        <group group_id="B10">
          <title>SHP639 0.6% Repeated BID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.6% applied topically in both the designated eye and non study eye twice daily (BID) during the repeated twice daily dose regimen.</description>
        </group>
        <group group_id="B11">
          <title>Placebo TID</title>
          <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.1%, 0.3%, 0.6% respectively applied topically in the designated eye and non study eye thrice daily (TID) during the thrice daily dose regimen.</description>
        </group>
        <group group_id="B12">
          <title>SHP639 0.1% TID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.1% applied topically in the designated eye and non study eye thrice daily (TID) during the thrice daily dose regimen.</description>
        </group>
        <group group_id="B13">
          <title>SHP639 0.3% TID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.3% applied topically in the designated eye and non study eye thrice daily (TID) during the thrice daily dose regimen.</description>
        </group>
        <group group_id="B14">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="5"/>
            <count group_id="B8" value="5"/>
            <count group_id="B9" value="2"/>
            <count group_id="B10" value="5"/>
            <count group_id="B11" value="4"/>
            <count group_id="B12" value="5"/>
            <count group_id="B13" value="5"/>
            <count group_id="B14" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" spread="7.77"/>
                    <measurement group_id="B2" value="63.8" spread="7.46"/>
                    <measurement group_id="B3" value="67.6" spread="6.39"/>
                    <measurement group_id="B4" value="59.0" spread="2.74"/>
                    <measurement group_id="B5" value="68.7" spread="8.19"/>
                    <measurement group_id="B6" value="72.8" spread="8.58"/>
                    <measurement group_id="B7" value="69.0" spread="7.31"/>
                    <measurement group_id="B8" value="68.2" spread="6.69"/>
                    <measurement group_id="B9" value="70.0" spread="4.24"/>
                    <measurement group_id="B10" value="74.6" spread="5.18"/>
                    <measurement group_id="B11" value="67.5" spread="18.38"/>
                    <measurement group_id="B12" value="70.8" spread="14.04"/>
                    <measurement group_id="B13" value="69.4" spread="4.93"/>
                    <measurement group_id="B14" value="68.4" spread="8.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Event (TEAE)</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose.</description>
        <time_frame>From start of study drug administration up to follow-up (Day 88)</time_frame>
        <population>Safety set consisted of all participants who were randomized and who received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.1%, 0.3%, 0.6% respectively applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
          </group>
          <group group_id="O2">
            <title>SHP639 0.1% QD</title>
            <description>Participants received one drop of SHP639 at a dose of 0.1% applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
          </group>
          <group group_id="O3">
            <title>SHP639 0.3% QD</title>
            <description>Participants received one drop of SHP639 at a dose of 0.3% applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
          </group>
          <group group_id="O4">
            <title>SHP639 0.6% QD</title>
            <description>Participants received one drop of SHP639 at a dose of 0.6% applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
          </group>
          <group group_id="O5">
            <title>Placebo BID</title>
            <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.1%, 0.3%, 0.6% respectively applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
          </group>
          <group group_id="O6">
            <title>SHP639 0.1% BID</title>
            <description>Participants received one drop of SHP639 at a dose of 0.1% applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
          </group>
          <group group_id="O7">
            <title>SHP639 0.3% BID</title>
            <description>Participants received one drop of SHP639 at a dose of 0.3% applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen..</description>
          </group>
          <group group_id="O8">
            <title>SHP639 0.6% BID</title>
            <description>Participants received one drop of SHP639 at a dose of 0.6% applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Repeated BID</title>
            <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.6% applied topically in the designated eye and non study eye twice daily (BID) during the repeated twice daily dose regimen.</description>
          </group>
          <group group_id="O10">
            <title>SHP639 0.6% Repeated BID</title>
            <description>Participants received one drop of SHP639 at a dose of 0.6% applied topically in both the designated eye and non study eye twice daily (BID) during the repeated twice daily dose regimen.</description>
          </group>
          <group group_id="O11">
            <title>Placebo TID</title>
            <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.1%, 0.3%, 0.6% respectively applied topically in the designated eye and non study eye thrice daily (TID) during the thrice daily dose regimen.</description>
          </group>
          <group group_id="O12">
            <title>SHP639 0.1% TID</title>
            <description>Participants received one drop of SHP639 at a dose of 0.1% applied topically in the designated eye and non study eye thrice daily (TID) during the thrice daily dose regimen.</description>
          </group>
          <group group_id="O13">
            <title>SHP639 0.3% TID</title>
            <description>Participants received one drop of SHP639 at a dose of 0.3% applied topically in the designated eye and non study eye thrice daily (TID) during the thrice daily dose regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Event (TEAE)</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose.</description>
          <population>Safety set consisted of all participants who were randomized and who received at least 1 dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Intra Ocular Pressure (IOP) at Day 29</title>
        <description>IOP was measured using Goldmann applanation tonometry and reported data from baseline at day 29 for both study eye and non study eye.</description>
        <time_frame>Baseline, Day 29</time_frame>
        <population>Pharmacodynamic (PD) set consisted of all participants in the safety set for whom the primary PD data were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.1%, 0.3%, 0.6% respectively applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
          </group>
          <group group_id="O2">
            <title>SHP639 0.1% QD</title>
            <description>Participants received one drop of SHP639 at a dose of 0.1% applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
          </group>
          <group group_id="O3">
            <title>SHP639 0.3% QD</title>
            <description>Participants received one drop of SHP639 at a dose of 0.3% applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
          </group>
          <group group_id="O4">
            <title>SHP639 0.6% QD</title>
            <description>Participants received one drop of SHP639 at a dose of 0.6% applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
          </group>
          <group group_id="O5">
            <title>Placebo BID</title>
            <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.1%, 0.3%, 0.6% respectively applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
          </group>
          <group group_id="O6">
            <title>SHP639 0.1% BID</title>
            <description>Participants received one drop of SHP639 at a dose of 0.1% applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
          </group>
          <group group_id="O7">
            <title>SHP639 0.3% BID</title>
            <description>Participants received one drop of SHP639 at a dose of 0.3% applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
          </group>
          <group group_id="O8">
            <title>SHP639 0.6% BID</title>
            <description>Participants received one drop of SHP639 at a dose of 0.6% applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Repeated BID</title>
            <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.6% applied topically in the designated eye and non study eye twice daily (BID) during the repeated twice daily dose regimen.</description>
          </group>
          <group group_id="O10">
            <title>SHP639 0.6% Repeated BID</title>
            <description>Participants received one drop of SHP639 at a dose of 0.6% applied topically in both the designated eye and non study eye twice daily (BID) during the repeated twice daily dose regimen.</description>
          </group>
          <group group_id="O11">
            <title>Placebo TID</title>
            <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.1%, 0.3%, 0.6% respectively applied topically in the designated eye and non study eye thrice daily (TID) during the thrice daily dose regimen.</description>
          </group>
          <group group_id="O12">
            <title>SHP639 0.1% TID</title>
            <description>Participants received one drop of SHP639 at a dose of 0.1% applied topically in the designated eye and non study eye thrice daily (TID) during the thrice daily dose regimen.</description>
          </group>
          <group group_id="O13">
            <title>SHP639 0.3% TID</title>
            <description>Participants received one drop of SHP639 at a dose of 0.3% applied topically in the designated eye and non study eye thrice daily (TID) during the thrice daily dose regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Intra Ocular Pressure (IOP) at Day 29</title>
          <description>IOP was measured using Goldmann applanation tonometry and reported data from baseline at day 29 for both study eye and non study eye.</description>
          <population>Pharmacodynamic (PD) set consisted of all participants in the safety set for whom the primary PD data were evaluable.</population>
          <units>millimeter of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="1.294"/>
                    <measurement group_id="O2" value="-1.20" spread="1.605"/>
                    <measurement group_id="O3" value="0.45" spread="1.515"/>
                    <measurement group_id="O4" value="0.40" spread="1.084"/>
                    <measurement group_id="O5" value="0.38" spread="1.539"/>
                    <measurement group_id="O6" value="0.44" spread="1.972"/>
                    <measurement group_id="O7" value="-0.20" spread="0.837"/>
                    <measurement group_id="O8" value="-0.40" spread="2.826"/>
                    <measurement group_id="O9" value="-0.13" spread="2.652"/>
                    <measurement group_id="O10" value="-2.00" spread="1.490"/>
                    <measurement group_id="O11" value="-1.13" spread="4.539"/>
                    <measurement group_id="O12" value="0.10" spread="0.929"/>
                    <measurement group_id="O13" value="-4.65" spread="3.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Study Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="1.430"/>
                    <measurement group_id="O2" value="-1.50" spread="0.354"/>
                    <measurement group_id="O3" value="1.20" spread="2.087"/>
                    <measurement group_id="O4" value="0.70" spread="0.908"/>
                    <measurement group_id="O5" value="0.83" spread="1.393"/>
                    <measurement group_id="O6" value="0.50" spread="1.061"/>
                    <measurement group_id="O7" value="-0.20" spread="0.758"/>
                    <measurement group_id="O8" value="-0.25" spread="2.610"/>
                    <measurement group_id="O9" value="-1.00" spread="4.243"/>
                    <measurement group_id="O10" value="-1.80" spread="2.260"/>
                    <measurement group_id="O11" value="0.00" spread="3.889"/>
                    <measurement group_id="O12" value="-0.10" spread="1.421"/>
                    <measurement group_id="O13" value="-3.85" spread="2.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of study drug administration up to follow-up (day 88)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo QD</title>
          <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.1%, 0.3%, 0.6% respectively applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
        </group>
        <group group_id="E2">
          <title>SHP639 0.1% QD</title>
          <description>Participants received one drop of SHP639 at a dose of 0.1% applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
        </group>
        <group group_id="E3">
          <title>SHP639 0.3% QD</title>
          <description>Participants received one drop of SHP639 at a dose of 0.3% applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
        </group>
        <group group_id="E4">
          <title>SHP639 0.6% QD</title>
          <description>Participants received one drop of SHP639 at a dose of 0.6% applied topically in the designated eye once daily (QD) during the once daily dose regimen.</description>
        </group>
        <group group_id="E5">
          <title>Placebo BID</title>
          <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.1%, 0.3%, 0.6% respectively applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
        </group>
        <group group_id="E6">
          <title>SHP639 0.1% BID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.1% applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
        </group>
        <group group_id="E7">
          <title>SHP639 0.3% BID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.3% applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
        </group>
        <group group_id="E8">
          <title>SHP639 0.6% BID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.6% applied topically in the designated eye and non study eye twice daily (BID) during the twice daily dose regimen.</description>
        </group>
        <group group_id="E9">
          <title>Placebo Repeated BID</title>
          <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.6% applied topically in the designated eye and non study eye twice daily (BID) during the repeated twice daily dose regimen.</description>
        </group>
        <group group_id="E10">
          <title>SHP639 0.6% Repeated BID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.6% applied topically in both the designated eye and non study eye twice daily (BID) during the repeated twice daily dose regimen.</description>
        </group>
        <group group_id="E11">
          <title>Placebo TID</title>
          <description>Participants received one drop of placebo matched to SHP639 at a dose of 0.1%, 0.3%, 0.6% respectively applied topically in the designated eye and non study eye thrice daily (TID) during the thrice daily dose regimen.</description>
        </group>
        <group group_id="E12">
          <title>SHP639 0.1% TID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.1% applied topically in the designated eye and non study eye thrice daily (TID) during the thrice daily dose regimen.</description>
        </group>
        <group group_id="E13">
          <title>SHP639 0.3% TID</title>
          <description>Participants received one drop of SHP639 at a dose of 0.3% applied topically in the designated eye and non study eye thrice daily (TID) during the thrice daily dose regimen.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal sensation in eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Eyelid margin crusting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Instillation site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="7" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Vital dye staining cornea present</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E10" events="7" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Shire</organization>
      <phone>+1 866 842 5335</phone>
      <email>ClinicalTransparency@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

